2024 Q2 Form 10-Q Financial Statement
#000140464424000057 Filed on May 10, 2024
Income Statement
| Concept | 2024 Q2 | 2024 Q1 | 2023 Q1 |
|---|---|---|---|
| Revenue | $925.0K | $0.00 | $0.00 |
| YoY Change | |||
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $5.315M | $5.238M | $4.027M |
| YoY Change | 52.21% | 30.07% | -13.66% |
| % of Gross Profit | |||
| Research & Development | $15.74M | $13.54M | $7.690M |
| YoY Change | -3795.77% | 76.09% | -28.14% |
| % of Gross Profit | |||
| Depreciation & Amortization | $800.0K | $800.0K | $329.0K |
| YoY Change | 938.96% | 143.16% | -19.95% |
| % of Gross Profit | |||
| Operating Expenses | $21.06M | $18.78M | $15.14M |
| YoY Change | 586.86% | 24.08% | 41.44% |
| Operating Profit | -$20.13M | -$18.78M | -$15.14M |
| YoY Change | 556.69% | 24.08% | -1.5% |
| Interest Expense | $2.031M | $3.000K | $945.0K |
| YoY Change | 107.03% | -99.68% | 6650.0% |
| % of Operating Profit | |||
| Other Income/Expense, Net | -$389.0K | -$459.0K | -$14.00K |
| YoY Change | 3178.57% | -200.0% | |
| Pretax Income | -$18.49M | -$16.92M | -$14.20M |
| YoY Change | 786.91% | 19.13% | -7.47% |
| Income Tax | |||
| % Of Pretax Income | |||
| Net Earnings | -$18.49M | -$16.92M | -$14.20M |
| YoY Change | 786.91% | 19.13% | -7.47% |
| Net Earnings / Revenue | -1999.14% | ||
| Basic Earnings Per Share | -$1.09 | -$1.00 | -$0.26 |
| Diluted Earnings Per Share | -$1.09 | -$1.00 | -$0.26 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 12.98M shares | 12.85M shares | 42.82M shares |
| Diluted Shares Outstanding | 16.94M shares | 16.90M shares | 55.42M shares |
Balance Sheet
| Concept | 2024 Q2 | 2024 Q1 | 2023 Q1 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $153.9M | $169.5M | $83.44M |
| YoY Change | 87.55% | 103.19% | -34.84% |
| Cash & Equivalents | $111.0M | $150.1M | $35.49M |
| Short-Term Investments | $42.87M | $19.39M | $47.94M |
| Other Short-Term Assets | $1.531M | $1.254M | $2.200M |
| YoY Change | -10.88% | -43.0% | -4.68% |
| Inventory | |||
| Prepaid Expenses | $3.066M | $2.765M | |
| Receivables | |||
| Other Receivables | |||
| Total Short-Term Assets | $159.1M | $174.1M | $85.64M |
| YoY Change | 89.96% | 103.35% | -34.31% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $16.06M | $16.48M | $2.489M |
| YoY Change | 2763.46% | 561.91% | -60.03% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $794.0K | $743.0K | $905.0K |
| YoY Change | 50.09% | -17.9% | -53.47% |
| Total Long-Term Assets | $20.67M | $21.21M | $12.82M |
| YoY Change | 102.19% | 65.39% | -31.65% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $159.1M | $174.1M | $85.64M |
| Total Long-Term Assets | $20.67M | $21.21M | $12.82M |
| Total Assets | $179.8M | $195.4M | $98.46M |
| YoY Change | 91.29% | 98.41% | -33.98% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $1.724M | $1.522M | $5.421M |
| YoY Change | -49.1% | -71.92% | -14.29% |
| Accrued Expenses | $7.144M | $6.824M | $1.431M |
| YoY Change | 379.46% | 376.87% | 17.68% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $52.00K | $43.00K | $304.0K |
| YoY Change | 1633.33% | -85.86% | 452.73% |
| Total Short-Term Liabilities | $13.07M | $11.82M | $7.156M |
| YoY Change | 167.89% | 65.15% | -5.79% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $53.00K | $53.00K | $7.000K |
| YoY Change | 783.33% | 657.14% | -89.39% |
| Other Long-Term Liabilities | $51.00K | $203.0K | $9.940M |
| YoY Change | -99.47% | -97.96% | -12.58% |
| Total Long-Term Liabilities | $51.00K | $203.0K | $9.947M |
| YoY Change | -99.47% | -97.96% | -13.03% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $13.07M | $11.82M | $7.156M |
| Total Long-Term Liabilities | $51.00K | $203.0K | $9.947M |
| Total Liabilities | $24.81M | $24.57M | $17.10M |
| YoY Change | 71.94% | 43.68% | -10.14% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$222.6M | -$204.1M | -$465.3M |
| YoY Change | -52.37% | -56.13% | 13.8% |
| Common Stock | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $155.0M | $170.8M | $81.36M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $179.8M | $195.4M | $98.46M |
| YoY Change | 91.29% | 98.41% | -33.98% |
Cashflow Statement
| Concept | 2024 Q2 | 2024 Q1 | 2023 Q1 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$18.49M | -$16.92M | -$14.20M |
| YoY Change | 786.91% | 19.13% | -7.47% |
| Depreciation, Depletion And Amortization | $800.0K | $800.0K | $329.0K |
| YoY Change | 938.96% | 143.16% | -19.95% |
| Cash From Operating Activities | -$15.89M | -$21.70M | -$13.03M |
| YoY Change | 292.52% | 66.5% | -7.51% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $460.0K | $65.00K | $419.0K |
| YoY Change | 248.48% | -84.49% | -7.3% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | -$23.15M | $30.00M | $11.13M |
| YoY Change | 8198.92% | 169.66% | |
| Cash From Investing Activities | -$23.61M | $29.94M | $10.71M |
| YoY Change | 5645.5% | 179.61% | -2468.58% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 399.0K | -$6.524M | -$66.00K |
| YoY Change | -235.71% | 9784.85% | -149.62% |
| NET CHANGE | |||
| Cash From Operating Activities | -15.89M | -$21.70M | -$13.03M |
| Cash From Investing Activities | -23.61M | $29.94M | $10.71M |
| Cash From Financing Activities | 399.0K | -$6.524M | -$66.00K |
| Net Change In Cash | -39.11M | $1.761M | -$2.393M |
| YoY Change | 722.63% | -173.59% | -83.39% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$15.89M | -$21.70M | -$13.03M |
| Capital Expenditures | $460.0K | $65.00K | $419.0K |
| Free Cash Flow | -$16.35M | -$21.77M | -$13.45M |
| YoY Change | 291.13% | 61.8% | -7.5% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2024Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
11818000 | usd |
| CY2023Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
22973000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
11642000 | usd |
| CY2023Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
12302000 | usd |
| CY2024Q1 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
53000 | usd |
| CY2023Q4 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
65000 | usd |
| CY2024Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-18779000 | usd |
| CY2023Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-13035000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-16921000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-12263000 | usd |
| CY2023Q4 | us-gaap |
Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
|
0.25 | |
| CY2024Q1 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | segment |
| CY2024Q1 | ngne |
Intellectual Property Contingent Value Rights Liability Current
IntellectualPropertyContingentValueRightsLiabilityCurrent
|
329000 | usd |
| CY2023Q4 | ngne |
Intellectual Property Contingent Value Rights Liability Current
IntellectualPropertyContingentValueRightsLiabilityCurrent
|
0 | usd |
| CY2024Q1 | us-gaap |
Asset Acquisition Contingent Consideration Liability Noncurrent
AssetAcquisitionContingentConsiderationLiabilityNoncurrent
|
857000 | usd |
| CY2023Q4 | us-gaap |
Asset Acquisition Contingent Consideration Liability Noncurrent
AssetAcquisitionContingentConsiderationLiabilityNoncurrent
|
1006000 | usd |
| CY2024Q1 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
203000 | usd |
| CY2023Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
203000 | usd |
| CY2024Q1 | us-gaap |
Liabilities
Liabilities
|
24573000 | usd |
| CY2023Q4 | us-gaap |
Liabilities
Liabilities
|
36549000 | usd |
| CY2023Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.000001 | |
| CY2024Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.000001 | |
| CY2024Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
50000000 | shares |
| CY2023Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
50000000 | shares |
| CY2023Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2024Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2023Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2024Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | usd |
| CY2023Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | usd |
| CY2024Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.000001 | |
| CY2023Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.000001 | |
| CY2024Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
450000000 | shares |
| CY2023Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
450000000 | shares |
| CY2023Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
12823665 | shares |
| CY2023Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
12823665 | shares |
| CY2024Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
0 | usd |
| CY2023Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
0 | usd |
| CY2024Q1 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
374852000 | usd |
| CY2023Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
373178000 | usd |
| CY2024Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-204075000 | usd |
| CY2023Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-187154000 | usd |
| CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
170777000 | usd |
| CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
186024000 | usd |
| CY2024Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
195350000 | usd |
| CY2023Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
222573000 | usd |
| CY2024Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
13541000 | usd |
| CY2023Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
10283000 | usd |
| CY2024Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
5238000 | usd |
| CY2023Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2752000 | usd |
| CY2024Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
18779000 | usd |
| CY2023Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
13035000 | usd |
| CY2024Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
2320000 | usd |
| CY2023Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
777000 | usd |
| CY2024Q1 | us-gaap |
Interest Expense
InterestExpense
|
3000 | usd |
| CY2023Q1 | us-gaap |
Interest Expense
InterestExpense
|
2000 | usd |
| CY2024Q1 | us-gaap |
Other Nonoperating Income
OtherNonoperatingIncome
|
143000 | usd |
| CY2023Q1 | us-gaap |
Other Nonoperating Income
OtherNonoperatingIncome
|
0 | usd |
| CY2024Q1 | us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
602000 | usd |
| CY2023Q1 | us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
3000 | usd |
| CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.00 | |
| CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.00 | |
| CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.00 | |
| CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.00 | |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
16903735 | shares |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
16903735 | shares |
| CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
186024000 | usd |
| CY2024Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1045000 | usd |
| CY2024Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
629000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-16921000 | usd |
| CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
170777000 | usd |
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-145739000 | usd |
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
293000 | usd |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
112000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-12263000 | usd |
| CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-157597000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-16921000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-12263000 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1045000 | usd |
| CY2023Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
293000 | usd |
| CY2024Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
814000 | usd |
| CY2023Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
812000 | usd |
| CY2024Q1 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
91000 | usd |
| CY2023Q1 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
0 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
176000 | usd |
| CY2023Q1 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
160000 | usd |
| CY2024Q1 | us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
11000 | usd |
| CY2023Q1 | us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
6000 | usd |
| CY2024Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
446000 | usd |
| CY2023Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
0 | usd |
| CY2024Q1 | ngne |
Increase Decrease In Business Development Contingent Value Rights Liability
IncreaseDecreaseInBusinessDevelopmentContingentValueRightsLiability
|
329000 | usd |
| CY2023Q1 | ngne |
Increase Decrease In Business Development Contingent Value Rights Liability
IncreaseDecreaseInBusinessDevelopmentContingentValueRightsLiability
|
0 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
1417000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
780000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-21000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
0 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
135000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
825000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-4879000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-2444000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-609000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-164000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-21650000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-13555000 | usd |
| CY2024Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
65000 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
29000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
|
30000000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
|
0 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
29935000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-29000 | usd |
| CY2024Q1 | us-gaap |
Payments Of Financing Costs
PaymentsOfFinancingCosts
|
4287000 | usd |
| CY2023Q1 | us-gaap |
Payments Of Financing Costs
PaymentsOfFinancingCosts
|
0 | usd |
| CY2024Q1 | us-gaap |
Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
|
2855000 | usd |
| CY2023Q1 | us-gaap |
Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
|
0 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
629000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
112000 | usd |
| CY2024Q1 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
11000 | usd |
| CY2023Q1 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
5000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-6524000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
107000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
1761000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-13477000 | usd |
| CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
148718000 | usd |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
82021000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
150479000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
68544000 | usd |
| CY2024Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
|
60000 | usd |
| CY2023Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
|
0 | usd |
| CY2024Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
141000 | usd |
| CY2023Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
0 | usd |
| CY2024Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
3000 | usd |
| CY2023Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
2000 | usd |
| CY2023Q4 | ngne |
Reverse Merger Conversion Ratio
ReverseMergerConversionRatio
|
0.0756 | shares |
| CY2023Q4 | us-gaap |
Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
|
7231747 | shares |
| CY2023Q4 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
1825635 | shares |
| CY2024Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Risks and Uncertainties</span><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, successful development of technology, obtaining additional funding, protection of proprietary technology, compliance with government regulations, risks of failure of pre-clinical studies, clinical studies and clinical trials, the need to obtain marketing approval for its drug candidates and its consumer products, fluctuations in operating results, economic pressure impacting therapeutic pricing, dependence on key personnel, risks associated with changes in technologies, development by competitors of technological innovations and the ability to transition from pilot scale manufacturing to large scale production.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Financial Condition</span></div><div style="margin-top:10pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Since its inception, the Company has funded its operations primarily with proceeds from the sales of equity securities and has incurred significant recurring losses, including net losses of $16.9 million and $12.3 million for the three months ended March 31, 2024 and 2023, respectively. In addition, the Company used cash in operations of $21.7 million and $13.6 million for the three months ended March 31, 2024 and 2023, respectively, and had an accumulated deficit of $204.1 million as of March 31, 2024. Management expects to incur substantial and increasing losses in future periods as the Company advances its products through its clinical and regulatory process and will rely on outside capital to fund its operations for the foreseeable future. The Company has not generated positive cash flows from operations, and there are no assurances that the Company will be successful in obtaining an adequate level of financing for the development and commercialization of its product candidates.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, the Company had cash, cash equivalents and investments of approximately $169.5 million. On December 18, 2023, the Company closed the reverse merger and the Pre-Closing Financing. The Company expects its available cash and cash equivalents on hand as of the issuance date </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of these financial statements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will be sufficient to fund its obligations as they become due for at least one year beyond the issuance date of these financial statements. As a result of the reverse merger with Neoleukin Therapeutics, the Company assumed an ATM or “at-the-market” Equity Offering Sales Agreement with BofA Securities, Inc., as agent (“BofA”), pursuant to which the Company was able to offer and sell, from time to time through BofA, shares of the Company’s common stock, having an aggregate offering price of up to $40.0 million. The Registration Statement on Form S-3 that was prepared for the ATM expired on December 21, 2023, and in March 2024, the Company formally terminated the ATM.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the Company is unable to secure additional outside capital, management will be required to seek other alternatives which may include, among others, a delay or termination of clinical trials or the development of its product candidates, temporary or permanent curtailment of the Company’s operations, a sale of assets, or other alternatives with strategic or financial partners. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties. Accordingly, the condensed consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.</span></div> | |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-16900000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-12300000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-21700000 | usd |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
16903735 | shares |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
16903735 | shares |
| CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.00 | |
| CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.00 | |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-13600000 | usd |
| CY2024Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-204100000 | usd |
| CY2024Q1 | us-gaap |
Investments And Cash
InvestmentsAndCash
|
169500000 | usd |
| CY2024Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. In preparing these financial statements, management used significant estimates in the following areas, among others: recoverability of the Company’s net deferred tax assets and related valuation allowance, useful lives and recoverability of property and equipment, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determining the incremental borrowing rate for calculating lease liabilities and related right-of-use assets and finance lease assets, clinical trial accruals, accrual estimates for all contingent value rights (“CVRs”), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the value attributed to employee stock options and other stock-based awards, and valuation of common stock. On an ongoing basis, the Company reviews its estimates to ensure that they appropriately reflect changes in the business or as new information becomes available. Actual results may differ from these estimates.</span></div> | |
| CY2024Q1 | us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
1 | segment |
| CY2024Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
150140000 | usd |
| CY2023Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
148210000 | usd |
| CY2024Q1 | us-gaap |
Restricted Cash
RestrictedCash
|
339000 | usd |
| CY2023Q4 | us-gaap |
Restricted Cash
RestrictedCash
|
508000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
150479000 | usd |
| CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
148718000 | usd |
| CY2024Q1 | us-gaap |
Restricted Cash
RestrictedCash
|
300000 | usd |
| CY2024Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div>Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company’s cash and cash equivalent accounts, at times, may exceed federally insured limits. As of March 31, 2024, the Company had $149.9 million in excess of the federally insured limits. The Company places its cash in financial institutions that management believes to be of high credit quality. | |
| CY2024Q1 | ngne |
Cash And Cash Equivalents At Or Above Fdic Insurance Limits
CashAndCashEquivalentsAtOrAboveFDICInsuranceLimits
|
149900000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-16921000 | usd |
| CY2024Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
1475458 | shares |
| CY2023Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
106920461 | shares |
| CY2023Q1 | ngne |
Reverse Merger Conversion Ratio
ReverseMergerConversionRatio
|
0.0756 | shares |
| CY2024Q1 | us-gaap |
Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss
DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss
|
164618000 | usd |
| CY2024Q1 | us-gaap |
Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
|
0 | usd |
| CY2024Q1 | us-gaap |
Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
|
1000 | usd |
| CY2024Q1 | us-gaap |
Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
|
164617000 | usd |
| CY2023Q4 | us-gaap |
Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss
DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss
|
193305000 | usd |
| CY2023Q4 | us-gaap |
Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
|
16000 | usd |
| CY2023Q4 | us-gaap |
Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
|
0 | usd |
| CY2023Q4 | us-gaap |
Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
|
193321000 | usd |
| CY2024Q1 | ngne |
Refunds And Other Receivables Current
RefundsAndOtherReceivablesCurrent
|
589000 | usd |
| CY2023Q4 | ngne |
Refunds And Other Receivables Current
RefundsAndOtherReceivablesCurrent
|
600000 | usd |
| CY2024Q1 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
2765000 | usd |
| CY2023Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
1496000 | usd |
| CY2024Q1 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
1254000 | usd |
| CY2023Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
1095000 | usd |
| CY2024Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
4608000 | usd |
| CY2023Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
3191000 | usd |
| CY2024Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
25267000 | usd |
| CY2023Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
25183000 | usd |
| CY2024Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
8792000 | usd |
| CY2023Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
8009000 | usd |
| CY2024Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
16475000 | usd |
| CY2023Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
17174000 | usd |
| CY2024Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
800000 | usd |
| CY2023Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
800000 | usd |
| CY2024Q1 | us-gaap |
Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
|
100000 | usd |
| CY2024Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1109000 | usd |
| CY2023Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
3496000 | usd |
| CY2024Q1 | ngne |
Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
|
4728000 | usd |
| CY2023Q4 | ngne |
Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
|
4895000 | usd |
| CY2024Q1 | ngne |
Accrued Severance Bonus And Retention Costs Current
AccruedSeveranceBonusAndRetentionCostsCurrent
|
68000 | usd |
| CY2023Q4 | ngne |
Accrued Severance Bonus And Retention Costs Current
AccruedSeveranceBonusAndRetentionCostsCurrent
|
2476000 | usd |
| CY2024Q1 | ngne |
Accrued Stock Issuance Costs Current
AccruedStockIssuanceCostsCurrent
|
0 | usd |
| CY2023Q4 | ngne |
Accrued Stock Issuance Costs Current
AccruedStockIssuanceCostsCurrent
|
3334000 | usd |
| CY2024Q1 | ngne |
Accrued Asset Acquisition Transaction Costs Current
AccruedAssetAcquisitionTransactionCostsCurrent
|
0 | usd |
| CY2023Q4 | ngne |
Accrued Asset Acquisition Transaction Costs Current
AccruedAssetAcquisitionTransactionCostsCurrent
|
2557000 | usd |
| CY2024Q1 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
919000 | usd |
| CY2023Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
737000 | usd |
| CY2024Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
6824000 | usd |
| CY2023Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
17495000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
524000 | usd |
| CY2023Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
259000 | usd |
| CY2024Q1 | us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
11000 | usd |
| CY2023Q1 | us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
6000 | usd |
| CY2024Q1 | us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
3000 | usd |
| CY2023Q1 | us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
2000 | usd |
| CY2024Q1 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
331000 | usd |
| CY2023Q1 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
54000 | usd |
| CY2024Q1 | us-gaap |
Short Term Lease Cost
ShortTermLeaseCost
|
23000 | usd |
| CY2023Q1 | us-gaap |
Short Term Lease Cost
ShortTermLeaseCost
|
23000 | usd |
| CY2024Q1 | us-gaap |
Lease Cost
LeaseCost
|
892000 | usd |
| CY2023Q1 | us-gaap |
Lease Cost
LeaseCost
|
344000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
2923000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
3987000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
3695000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
3239000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
3294000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
|
616000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
17754000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
3442000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
14312000 | usd |
| CY2024Q1 | us-gaap |
Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
|
38000 | usd |
| CY2024Q1 | us-gaap |
Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
|
50000 | usd |
| CY2024Q1 | us-gaap |
Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
|
15000 | usd |
| CY2024Q1 | us-gaap |
Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
|
6000 | usd |
| CY2024Q1 | us-gaap |
Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
|
109000 | usd |
| CY2024Q1 | us-gaap |
Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
|
13000 | usd |
| CY2024Q1 | us-gaap |
Finance Lease Liability
FinanceLeaseLiability
|
96000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
3565000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
2670000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
11642000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
14312000 | usd |
| CY2024Q1 | us-gaap |
Finance Lease Right Of Use Asset Before Accumulated Amortization
FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
|
87000 | usd |
| CY2024Q1 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
43000 | usd |
| CY2024Q1 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
53000 | usd |
| CY2024Q1 | us-gaap |
Finance Lease Liability
FinanceLeaseLiability
|
96000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1306000 | usd |
| CY2024Q1 | us-gaap |
Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
|
13000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P4Y7M20D | |
| CY2024Q1 | us-gaap |
Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
|
P2Y3M18D | |
| CY2024Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0972 | |
| CY2024Q1 | us-gaap |
Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
|
0.1149 | |
| CY2024Q1 | us-gaap |
Asset Acquisition Consideration Transferred Contingent Consideration
AssetAcquisitionConsiderationTransferredContingentConsideration
|
1300000 | usd |
| CY2024Q1 | us-gaap |
Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
|
281000 | usd |
| CY2024Q1 | us-gaap |
Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
|
598000 | usd |
| CY2024Q1 | us-gaap |
Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
|
408000 | usd |
| CY2024Q1 | us-gaap |
Contractual Obligation
ContractualObligation
|
1287000 | usd |
| CY2024Q1 | ngne |
Collaborative Arrangement Rights And Obligations Upfront Payment Percentage
CollaborativeArrangementRightsAndObligationsUpfrontPaymentPercentage
|
0.80 | |
| CY2024Q1 | ngne |
Intellectual Property Contingent Value Rights Liability Current
IntellectualPropertyContingentValueRightsLiabilityCurrent
|
300000 | usd |
| CY2024Q1 | ngne |
Intellectual Property Contingent Value Rights Liability Current
IntellectualPropertyContingentValueRightsLiabilityCurrent
|
300000 | usd |
| CY2024Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
450000000 | shares |
| CY2024Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.000001 | |
| CY2024Q1 | ngne |
Percentage Of Outstanding Stock Per Stockholder Maximum
PercentageOfOutstandingStockPerStockholderMaximum
|
0.0999 | |
| CY2024Q1 | ngne |
Percentage Of Outstanding Stock Per Stockholder Upon Notice Maximum
PercentageOfOutstandingStockPerStockholderUponNoticeMaximum
|
0.1999 | |
| CY2024Q1 | ngne |
Class Of Warrant Or Right Notice Period
ClassOfWarrantOrRightNoticePeriod
|
P61D | |
| CY2024Q1 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
3484474 | shares |
| CY2023Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
3061555 | shares |
| CY2024Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1045000 | usd |
| CY2023Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
293000 | usd |
| CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
823833 | shares |
| CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
31.43 | |
| CY2023 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P5Y10M20D | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
741652 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
34.59 | |
| CY2024Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
37330 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
16.89 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
|
52697 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
|
72.62 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1475458 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
31.03 | |
| CY2024Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y9M7D | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
530779 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
30.95 | |
| CY2024Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P5Y1M24D | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
32200000 | usd |
| CY2024Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
15100000 | usd |
| CY2024Q1 | ngne |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedIntrinsicValue
|
700000 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
25.97 | |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
12.99 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
|
0.8639 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
|
0.8764 | |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
|
0.8296 | |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
|
0.8370 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0397 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0432 | |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0345 | |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0446 | |
| CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
|
0 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
|
482384 | shares |
| CY2024Q1 | ngne |
Number Of Shares Common Stock Holder To Receive When Restricted Stock Unit Vests
NumberOfSharesCommonStockHolderToReceiveWhenRestrictedStockUnitVests
|
1 | shares |
| CY2024Q1 | ecd |
Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
|
false | |
| CY2024Q1 | ecd |
Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
|
false | |
| CY2024Q1 | ecd |
Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
|
false | |
| CY2024Q1 | ecd |
Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
|
false |
